Legislative Activity
Track David's sponsored bills, co-sponsored legislation, and voting record
The Paws Off Act of 2025 requires warning labels on foods containing xylitol about its toxic effects on dogs, directing the FDA Commissioner to implement these labeling requirements through new rules.
David Schweikert
Representative
AZ
David Schweikert
Representative
AZ
The "Paws Off Act of 2025" mandates warning labels on food products containing xylitol, highlighting its toxicity to dogs. The Food and Drug Administration is directed to implement this labeling requirement through an interim rule within 6 months and a final rule within 1 year.
The JFK Act of 2025 mandates the immediate public disclosure of all unclassified records and information related to the assassination of President John F. Kennedy, overriding any existing conflicting laws or agreements. It also directs the Attorney General to petition courts to unseal any related records.
David Schweikert
Representative
AZ
David Schweikert
Representative
AZ
The JFK Act of 2025 mandates the public disclosure of all unclassified assassination records and information related to President John F. Kennedy's assassination, overriding any conflicting laws or prior restrictions. It requires covered Federal officials to release all unredacted records within 30 days of enactment. The Attorney General is directed to petition courts to unseal any relevant records, and such requests are automatically deemed to meet the legal standard for disclosure.
This bill requires the Secretary of Health and Human Services to provide guidance on Medicare payments for remote monitoring devices using artificial intelligence by January 1, 2027. The act is also known as the "Maintaining Innovation and Safe Technologies Act."
David Schweikert
Representative
AZ
David Schweikert
Representative
AZ
The Maintaining Innovation and Safe Technologies Act requires the Secretary of Health and Human Services to issue guidance by January 1, 2027, clarifying Medicare payments for remote monitoring devices utilizing artificial intelligence. This includes devices like continuous glucose monitors that transmit data to healthcare providers for patient care. The guidance aims to address how Medicare will handle payments for these innovative technologies.